Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE versus FERNISOLONE P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE versus FERNISOLONE P.
CELESTONE vs FERNISOLONE-P
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
None Documented
None Documented
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Corticosteroid
Corticosteroid